Novo Nordisk partners with Anthropic to use Claude AI for drug development

Sep 16, 2026

On September 16, 2026, Danish drugmaker Novo Nordisk announced a partnership with AI startup Anthropic to deploy Claude models, aiming to accelerate drug discovery and development. Novo Nordisk will integrate Claude Science into its R&D workflows and use frontier models to boost software development. The drugmaker already utilizes Claude to automate trial reports and reduce patient documentation timelines from months to minutes, highlighting the growing role of AI in pharmaceutical pipelines.

Novo Nordisk-Anthropic partnership

▪The collaboration between Novo Nordisk and Anthropic, announced on September 16, 2026, aims to address key challenges in the drug-discovery process by developing targeted solutions and workflows
▪Danish drugmaker Novo Nordisk partnered with artificial intelligence company Anthropic on September 16, 2026, to use Anthropic's Claude AI models to accelerate the discovery and development of new medicines
▪Novo Nordisk plans to use Anthropic's frontier models, as part of the partnership announced September 16, 2026, to strengthen the drugmaker's AI-driven software development

AI in pharmaceutical R&D

▪Pharmaceutical companies are increasingly adopting artificial intelligence technologies to accelerate research and development and improve efficiency across their drug pipelines
▪Novo Nordisk executive Mike Doustdar stated that artificial intelligence tools can offer new scientific opportunities and aid in reasoning and understanding human biology and drug mechanics
▪Artificial intelligence industry leaders remain split over the speed at which companies should develop increasingly powerful AI technologies

Claude for drug discovery

▪Anthropic Chief Executive Officer Dario Amodei stated that providing researchers access to frontier models can shorten research timelines, improve outcomes, and discover treatments that improve human life
▪Novo Nordisk will initially test Anthropic's AI models and Claude Science in the drugmaker's research and development workflows to address scientific problems

Automated trial report generation

▪Novo Nordisk already uses Anthropic's Claude AI to automate clinical trial report generation
▪Novo Nordisk uses Anthropic's Claude AI to reduce the timeline for creating patient documentation from months to minutes